{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:20:07Z","timestamp":1794932407718,"version":"4.9.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129069","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:07:04Z","timestamp":1787378824000},"page":"129069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Systematic review of the mutations in the active antigenic site \u00d8 of the prefusion F protein of the Respiratory Syncytial Virus (RSV) following the implementation of monoclonal antibody prophylaxis"],"prefix":"10.1016","volume":"91","author":[{"given":"Maria M.","family":"Berikopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth-Barbara","family":"Tatsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Siahanidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Michos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129069_bb0005","first-page":"18","article-title":"RSV disease in infants and young children: can we see a brighter future?","author":"Baraldi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.129069_bb0010","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/cid\/cix378","article-title":"Microorganisms associated with pneumonia in children <5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, case-control study","volume":"65","author":"B\u00e9net","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129069_bb0015","first-page":"17","article-title":"Respiratory syncytial virus disease burden in adults aged 60years and older in high-income countries: a systematic literature review and meta-analysis","author":"Savic","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2026.129069_bb0020","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.129069_bb0025","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.1128\/JVI.00256-14","article-title":"Structural analysis of respiratory syncytial virus reveals the position of M2-1 between the matrix protein and the ribonucleoprotein complex","volume":"88","author":"Kiss","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.129069_bb0030","first-page":"83","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2026.129069_bb0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcv.2018.02.004","article-title":"Genetic characterization of respiratory syncytial virus highlights a new BA genotype and emergence of the ON1 genotype in Lyon, France, between 2010 and 2014","volume":"102","author":"Gaymard","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2026.129069_bb0040","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1016\/j.vaccine.2018.09.056","article-title":"Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset","volume":"36","author":"Mas","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129069_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006602.pub4","article-title":"Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children","author":"Andabaka","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2026.129069_bb0050","article-title":"Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children","author":"Garegnani","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2026.129069_bb0055","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa2106062","article-title":"Prefusion F protein\u2013based respiratory syncytial virus immunization in pregnancy","volume":"386","author":"Sim\u00f5es","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.129069_bb0060","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/vaccines12060640","article-title":"Impact of nirsevimab immunization on pediatric hospitalization rates: a systematic review and meta-analysis (2024)","volume":"12","author":"Ricc\u00f2","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.129069_bb0065","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/v16060851","article-title":"Whole-genome sequencing and genetic diversity of human respiratory syncytial virus in patients with influenza-like illness in Sicily (Italy) from 2017 to 2023","volume":"16","author":"Tramuto","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.129069_bb0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season - new vaccine surveillance network, October 2023-February 2024","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.129069_bb0075","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/archdischild-2024-327153","article-title":"Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)","volume":"109","author":"Coma","year":"2024","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2026.129069_bb0080","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2352-4642(25)00093-8","article-title":"Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis","volume":"9","author":"Sumsuzzman","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2026.129069_bb0085","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamapediatrics.2025.5280","article-title":"Nirsevimab against hospitalizations and emergency department visits for lower respiratory tract infection in infants: a meta-analysis","volume":"180","author":"Sumsuzzman","year":"2026","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2026.129069_bb0090","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/infdis\/jiy189","article-title":"Prevalence and significance of substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization escape from antibody MEDI8897","volume":"218","author":"Zhu","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129069_bb0095","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.129069_bb0100","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.129069_bb0105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.129069_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.129069_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126276","article-title":"Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: an exploratory analysis of a phase 2\/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)","volume":"42","author":"Tuffy","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129069_bb0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamapediatrics.2024.5572","article-title":"Respiratory syncytial virus disease burden and nirsevimab effectiveness in young children from 2023-2024","volume":"179","author":"Moline","year":"2025","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2026.129069_bb0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(24)00570-X","article-title":"Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study","volume":"25","author":"Fourati","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129069_bb0130","article-title":"Evolutionary dynamics of HRSV following the implementation of nirsevimab immunoprophylaxis in Catalonia (2023-2024)","volume":"91","author":"Gonz\u00e1lez-S\u00e1nchez","year":"2025","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2026.129069_bb0135","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1038\/s41467-023-40057-8","article-title":"Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials","volume":"14","author":"Ahani","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.129069_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2026.04.003","article-title":"Genomic surveillance of respiratory syncytial virus during 2023\/2024 nirsevimab prophylaxis, Eastern Spain, early results","author":"Mengual-Chuli\u00e1","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2026.129069_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2026.101353","article-title":"Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France","volume":"7","author":"Fourati","year":"2026","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.129069_bb0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci"},{"key":"10.1016\/j.vaccine.2026.129069_bb0155","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S1473-3099(23)00062-2","article-title":"Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data","volume":"23","author":"Wilkins","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129069_bb0160","first-page":"12","article-title":"Respiratory syncytial virus strain evolution and mutations in Western Australia in the context of nirsevimab prophylaxis","author":"Lamichhane","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129069_bb0165","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/infdis\/jiae636","article-title":"Amino acid substitutions in the fusion protein of respiratory syncytial virus in Fukushima, Japan, during 2008\u20132023 and their effects","volume":"231","author":"Okabe","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129069_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115591","article-title":"Genetic variability of respiratory syncytial virus and its impact on monoclonal antibody binding sites: a national cross-sectional study during the 2023\u20132024 season","volume":"166","author":"Piralla","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2026.129069_bb0175","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1038\/s41467-024-47757-9","article-title":"Deviations in RSV epidemiological patterns and population structures in the United States following the COVID-19 pandemic","volume":"15","author":"Rios-Guzman","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.129069_bb0180","article-title":"Genomic evolution of human respiratory syncytial virus during a decade (2013\u22122023): bridging the path to monoclonal antibody surveillance","volume":"88","author":"Pi\u00f1ana","year":"2024","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2026.129069_bb0185","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jmii.2024.06.003","article-title":"Genetic characterization of respiratory syncytial virus surface glycoproteins F and G in Taiwan, 2017\u20132021","volume":"57","author":"Fang","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.vaccine.2026.129069_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007944","article-title":"Alternative conformations of a major antigenic site on RSV F","volume":"15","author":"Jones","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2026.129069_bb0195","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/v17060793","article-title":"Insights into the currently available drugs and investigational compounds against RSV with a focus on their drug-resistance profiles","volume":"17","author":"Magnapera","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.129069_bb0200","doi-asserted-by":"crossref","first-page":"10085","DOI":"10.1038\/s41467-024-54384-x","article-title":"A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.129069_bb0205","first-page":"32","article-title":"A systematic review on global RSV genetic data: identification of knowledge gaps","author":"Langedijk","year":"2022","journal-title":"Rev Med Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:48:09Z","timestamp":1794930489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26008789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"alternative-id":["S0264410X26008789"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of the mutations in the active antigenic site \u00d8 of the prefusion F protein of the Respiratory Syncytial Virus (RSV) following the implementation of monoclonal antibody prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129069"}}